Economic Indicators - The November consumer price index (CPI) report is expected to show a 12-month inflation rate of 3.1%, with a core CPI (excluding food and energy) forecasted at an annual rate of 3.0% [2] - The Bureau of Labor Statistics noted that the release will not include 1-month percent changes for November 2025 due to the cancellation of the October inflation report [3] IPO Market - Medline, a medical supply giant, had a successful IPO, with shares jumping 41% on its debut, bringing its market capitalization to approximately $54 billion after opening at $35, up from its $29 IPO price [4] - Over 200 IPOs have been priced this year despite market volatility, marking the largest U.S. listing since Rivian's $13.7 billion deal in November 2021 [5] Corporate Leadership Changes - Glen Hauenstein, president of Delta Air Lines, will retire at the end of February after 20 years with the company, during which he helped position Delta as a leader in profitability [7] - Some of Delta's strategies, such as raising entry requirements for its SkyClubs, have faced customer pushback [8]

If 21st-century markets were an episode of The Andy Griffith Show, this news might have cued Gomer Pyle’s trademark line, “Surprise, surprise, surprise.” The biggest IPO of 2025 has no connection to artificial intelligence, semiconductors or data centers. It’s for a company that makes hospital gowns. On Wednesday, shares of medical supply company Medline jumped 40% in their Nasdaq debut, closing at $40 a pop after being priced at $29 in an IPO valued at $6.3 billion. SUBSCRIBE:  Receive more of our free ...

Core Insights - Medline has launched the largest IPO in over four years with a $6.26 billion offering, marking a significant event in the healthcare sector [1] Company Overview - Medline is the largest provider of medical surgical products and supply chain solutions for the healthcare industry, with revenue primarily derived from product sales [1][2] - The company operates a membership model similar to Costco, providing healthcare providers with competitive pricing through its supply chain business [3] Financial Performance - Medline has demonstrated solid revenue growth, with increases of 8.3% in 2023, 9.8% in 2024, and 10.3% through the first nine months of 2025, indicating accelerating growth trends [4]

Core Insights - Medline Inc. shares are expected to open 16% higher than their IPO price, raising $6.26 billion in the largest IPO of the year [1][2] - The IPO pricing values Medline at approximately $39 billion, making it a significant player in the medical supply industry [2][5] - The successful IPO concludes the US IPO calendar for the year, setting a positive tone for future listings, including a potential SpaceX debut in 2026 [3] Company Overview - Medline manufactures and distributes essential medical supplies such as gloves, gowns, and exam tables for hospitals and doctors [1] - The company was acquired in a $34 billion leveraged buyout by Blackstone Inc., Carlyle Group Inc., and Hellman & Friedman in 2021 [1] Market Context - The IPO surpassed the previous largest listing of the year, which was a $5.26 billion offering by Contemporary Amperex Technology Co. Ltd. [2] - Medline's IPO is the largest in the US since Rivian Automotive Inc.'s $13.7 billion deal in 2021 [2] - The total amount raised from first-time share sales in the US this year exceeds $46 billion, indicating a strong market despite previous disruptions [4] Investment Details - Medline secured up to $2.35 billion in commitments from cornerstone investors, including notable firms like Baillie Gifford and Morgan Stanley [6] - The upsized offering included proceeds from over 37 million shares designated for purchasing stock from pre-IPO shareholders, allowing private equity firms to realize returns without selling shares outright [7]

Market Overview - The trading day ended with major indices down, with the Dow Jones Industrial Average falling over 200 points (0.5%), the S&P 500 down 78-79 points (1.2%), and the Nasdaq composite down about 400 points (1.8%) [7] - The S&P 500 closed below its 50-day moving average, indicating a bearish sentiment in the market [7][3] Sector Performance - Energy sector stocks saw a rise of approximately 2.2%, benefiting from increased energy demand [9] - Technology sector stocks faced significant declines, with a drop of about 2%, contributing to the overall market downturn [10] Company Highlights - Micron Technology reported strong earnings, with an EPS of $4.78, significantly beating the expected $3.95, and revenue of $13.64 billion, surpassing the anticipated $13 billion [11] - Micron's guidance for the next quarter indicates adjusted revenue between $18.3 billion to $19.1 billion, well above the expected $4.38 billion [17][18] - The stock of Micron has increased by 169% year-to-date, although it is down about 14% from its all-time high in December [13] IPO Activity - Medline, a medical supplies company, had a successful IPO, raising $6.25 billion and finishing the day up 41%, marking it as the largest IPO of the year [24] Notable Decliners - Nvidia was the biggest decliner in the S&P 500, down 3.8%, contributing 19 points to the index's decline [29] - Other notable declines included Broadcom down 4.5%, Tesla down 4.6%, and Oracle down 5.4% due to concerns over its data center project [30][31]

Medline (MDLN) stock rose 40% on Wednesday to close at $40.66, as investors warmly greeted the year's biggest IPO on one of the last trading days of the year. The medical supply giant said late Tuesday that it had raised $6.26 billion in its IPO, selling a little over 216 million shares at $29 each, with the stock set to begin trading on Wednesday. Based on a total Class A share count of around 1.3 billion, the company's market cap stood north of $50 billion at the close of trading on Wednesday. Privat ...

Company Overview - Medline, a key manufacturer and distributor of medical supplies, was founded in 1966 and is based in Northfield, Illinois. The company produces items such as surgical kits, gloves, and gowns used by hospitals globally [6][9] - Medline has maintained net sales growth every year since its inception, even through economic cycles and the COVID-19 pandemic [6] IPO Details - Medline shares surged over 40% during its New York debut, valuing the company at $54 billion, marking the largest US IPO since Rivian's listing in 2021 [1] - The company sold 216 million shares at an IPO price of $29 per share, raising $6.26 billion, making it the largest private-equity-backed IPO ever [2][4] - The stock opened at $35 and closed at $41 on its first day of trading [1] Financial Performance - For the nine months ending September 27, Medline reported a net income of $977 million on revenue of $20.6 billion, an increase from $911 million on $18.7 billion in the same period the previous year [11] Market Position and Strategy - Medline's dominant position in branded medical equipment has attracted investors, who appreciate its growth prospects and relative insulation from broader economic fluctuations [10] - The company operates 33 facilities, with about half of its output coming from the US or North America, allowing it to mitigate tariff impacts [7][9] - CEO Jim Boyle stated that the IPO will enable the company to reduce debt and enhance its market presence while continuing to operate as before [4][13] Industry Context - The IPO market in the US has shown resilience in 2025, with first-time share sales raising a total of $46.15 billion, the highest since 2021 [14] - The successful listing of Medline may encourage more private equity-backed firms to pursue IPOs [18]

The largest IPO of the year, Medline, opening for trading about 15 minutes ago at $35 per share. That's up more than 20% from its IPO price of $29 per share. The company, which makes supplies products uh supplies and products used in labs and surgeries, sold more shares than initially planned in an upsized deal, more than $6 billion worth.Medline has been private for 58 years with most of its tenure familyowned until its buyout by a consortium of private equity firms in 2021. The IPO market cap is about 20 ...

Medline shares opened at $35 each, versus the IPO price of $29, after the medical supplier raised $6.26 billion in the year's biggest initial public offering. Bailey Lipschultz reports on Bloomberg Television. ...

Core Viewpoint - The IPO of Medline, the largest of the year, opened at $35 per share, reflecting strong demand despite a generally weak IPO market [1][2] Group 1: IPO Performance - Medline's shares increased by over 20% from the IPO price of $29, indicating strong market interest [2] - The company raised more than $6 billion in an upsized deal, selling more shares than initially planned [2] - The current market capitalization of Medline is approximately $20 billion higher than the acquisition price by private equity firms four years ago [3] Group 2: Company Background - Medline has been a private company for 58 years, primarily family-owned until its buyout by private equity firms in 2021 [2] - The company has a significant debt load of about $17 billion, which it plans to address using IPO proceeds [3][4] - Medline has demonstrated consistent growth, with net sales increasing annually at a compound annual growth rate (CAGR) of 18% since inception [4] Group 3: Market Implications - The successful IPO and share performance, currently up about 27%, may signal a positive outlook for future IPOs, particularly for private equity-owned companies [5] - The performance of Medline's IPO could alleviate some challenges faced in the IPO market over the past few years, potentially reducing the backlog of companies waiting to go public [5]